Skip to content
Fiscal Receipts

Senate LDA lobbying filing

PFIZER INC.

Registrant: PFIZER INC. Year: 2025 Period: Fourth Quarter Type: 4A

View on lda.senate.gov ↗

Reported income

not reported

Reported expenses

$1.78M

Tracked program mentions5

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

  • Amphibious Combat Vehicle Family of Vehicles2025matched: “2025PE code cited directly

    Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing…

  • Enterprise Platforms and Capabilities - Software Pilot Program0608140D8Zmatched: “Platforms|Pilotmatched 2+ title words

    Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B…

  • Explosive Ordnance Disposal Equip5509matched: “5509PE code cited directly

    Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing…

  • Making, Maintaining, Supply Chain and Logistics0602025Ematched: “Supply|Chainmatched 2+ title words

    International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign…

  • SPQ-9B Radar2026matched: “2026PE code cited directly

    Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing…

Lobbying activities3

  • Health IssuesHCR

    Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies

  • Medicare/MedicaidMMM

    Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid

  • Trade (domestic/foreign)TRD

    International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues

Lobbyists8

  • ANGELA WILES
  • CATHERINE ROBINSON
  • ELISSA ALBEN
  • EMILY MUELLER
  • FRANCISCO CARRILLO
  • JENNIFER WALTON
  • MATTHEW STROIA
  • STEPHEN CLAEYS

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.